Your session is about to expire
← Back to Search
Risdiplam for Spinal Muscular Atrophy (SUNFISH Trial)
SUNFISH Trial Summary
This trial is testing a new drug for people with Type 2 or Type 3 SMA. The first part is to see if it's safe and tolerable, and the second part is to see if it works.
- Spinal Muscular Atrophy
SUNFISH Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 2 trial • 231 Patients • NCT02908685SUNFISH Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Does this research project include geriatric patients in its sample size?
"Children aged 2 to 25 can participate in this clinical trial. In total, there are 53 clinical trials underway for patients under 18 years old and 151 for patients over 65."
Are recruitment efforts ongoing for this clinical trial?
"The trial, which was first posted on 10/20/2016, is not recruiting patients at this time according to clinicaltrials.gov. However, there are 211 other trials that are currently looking for participants."
Are there a lot of hospitals running this clinical trial in Canada?
"This particular trial is being conducted at Columbia University Medical Center, The Neurological Institute of New york, Alberta Children's Hospital Division of Pediatric Neurology, and McGill University Health Centre - Glen Site. In addition, there are 5 other undisclosed locations."
What is the patient volume for this research?
"This study is not recruiting patients presently. The trial was initially posted on October 20th, 2016 and was last updated on August 31st, 2022. If the reader is looking for other trials, there are 205 trials actively recruiting participants with muscular atrophy and 6 studies for Risdiplam actively recruiting patients."
What makes this research project unique?
"Risdiplam has been under research since 2016 when the first study, sponsored by Hoffmann-La Roche, was completed with 231 participants. After the successful Phase 2 & 3 drug approval, 6 more active studies involving Risdiplam have popped up in 22 different cities and countries."
Can you give some examples of other investigations that have used Risdiplam?
"Risdiplam was first studied in the year 2016 at Jichi Medical University Hospital. So far, there have been 18243 completed trials. Currently, there are 6 live studies, a significant amount of which are based in New york City."
Share this study with friends
Copy Link
Messenger